Mar 7 |
Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Mar 6 |
Werewolf Therapeutics to Present at the 2024 Leerink Partners Global Biopharma Conference
|
Mar 5 |
Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024
|
Jan 8 |
Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook
|
Jan 4 |
Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors
|
Dec 29 |
Werewolf Therapeutics: Still In The Race To Develop Next Generation Cytokines
|
Dec 14 |
Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
|
Dec 7 |
Institutions profited after Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) market cap rose US$14m last week but private equity firms profited the most
|
Nov 22 |
Werewolf Therapeutics to Present at the Evercore ISI HealthCONx Conference
|
Nov 14 |
Werewolf Therapeutics GAAP EPS of -$0.23, revenue of $5.9M
|